menu

Quintiles Library

Precision Enrollment
Featured Video
Show Filters
White Paper
下一代测序技术将为肿瘤临床试验和癌症治疗带来革新
Explore More
White Paper
下一代测序技术将为肿瘤临床试验和癌症治疗带来革新
Explore More
White Paper
This insight brief examines the varied definitions and regulatory pathways for rare disease therapies. The authors describe QuintilesIMS’s proven patient centric approaches to study planning, innovative ways to accelerate patient recruitment through an efficient site strategy, and the importance of real-world evidence.
Explore More
Brochure
Getting a drug through clinical trials and successfully on to the market after regulatory approval is a long process, and it might be understandable for a company to metaphorically take a moment to catch its breath. Approval, however, is only the first step; the next big hurdle is to get the best positioning and market access for the drug, so that the right patients can...
Read More
Brochure
Managing long term conditions is challenging, for both patients and the healthcare system. Getting patients more involved in their care through patient support programs can help improve their outcomes and take the pressure off the healthcare system. Gain an understanding of why programs need to be tailored specifically to the patient, disease type and its stage. Learn...
Read More
White Paper
The future of medicine rests on data: the evidence that is the basis for the discovery, development and dispensing of prescription products and all other healthcare decisions. Data, and the analysis of that data, informs drug development, portfolio decisions, prescribing behaviors, patient compliance and reimbursement policy in value-based healthcare systems. Mastering...
Explore More
White Paper
Multiple myeloma is an extremely complex genomic disease that accounts for 1% of all cancers and 13% of all hematologic malignancies. Worldwide, approximately 86,000 new cases occur annually. Recently, clinical research in multiple myeloma has been very active, and various novel therapies are being investigated. This White Paper addresses several important components of...
Explore More
Presentation
Today’s diabetes clinical development landscape is competitive, complex, and in demand. Continuous Glucose Monitoring (CGM) has the potential to become the new gold-standard in diabetes clinical trials. CGM provides more robust glycemic data sets and glucose variability than ever before, which leads to better clinical outcomes and patient safety. Navigating and...
Explore More
Presentation
Drug development challenges drive the need to translate scientific and therapeutic advances to better outcomes. As such, developing the evidence you need to meet the needs of all stakeholders, including investors, regulators, payers, providers and patients, and proving value in the real-world becomes critical.In this webinar, QuintilesIMS experts Laura Marquis, John Doyle...
Explore More
Fact Sheet
For success in early clinical development, it’s critical to find the right participants, target dose/exposure, response and commercial strategy. A tailored delivery model that is proactive and scalable can help you meet these challenges – and accelerate your Phase I trial or program. Improve your probability of success with QuintilesIMS’s global drug development...
Read More
White Paper
Developing complex generics to adapt to a challenging drug development processGenerics have been an attractive, lucrative development path for more than three decades. As the market has become saturated with simple generic products, biopharma companies are turning their focus to complex generic drugs, which deliver more value to patients by addressing additional unmet...
Explore More
Presentation
As a senior leader in emerging biopharma, you know that examining your product development program through the lens of all stakeholders is critical for success. But are you clear on key metrics and milestones your key investors are seeking? Are you taking the appropriate steps in early clinical development to lay the groundwork for these metrics and navigate your clinical...
Explore More
Fact Sheet
Emerging biopharma companies are driving innovation in clinical development, creating new therapies, devices and diagnostics for the patients that need them most. Your focus on niche areas and unmet medical needs presents great opportunities, but also great challenges. Delayed enrollment, regulatory changes or unanticipated safety concerns can have a significant negative...
Read More
White Paper
QuintilesIMS authors, along with members of the Clinical Operations Group at the Sarah Cannon Research Institute, collaborated in writing this White Paper entitled “Managing Multi-Arm Studies in an Evolving Immuno-Oncology Landscape.”  Immunotherapy is a treatment strategy that targets the host immune system, not the tumor itself.  Early successes have led to much...
Explore More
White Paper
Epilepsy – which poses a serious burden for patients, with effects on quality of life, work productivity, healthcare needs and risk of premature death – is diagnosed in some 2.4 million people globally each year, and currently affects around 300,000 American children under the age of 14. Pediatric epilepsies present particular challenges, including correct diagnoses,...
Explore More
Article
Precision medicine promises a future where treatments are customized to the unique characteristics of the patient and their disease. At the heart of many projects is the search for genetic markers that can be used to predict, diagnose and track diseases and treatments, but genetics is only one small piece of the precision medicine puzzle.
Explore More
Fact Sheet
Having a committed project management team is essential for success in your clinical development projects. You need a partner with the right data and resources as well as the expertise for superior delivery. Partner with QuintilesIMS to drive healthcare forward.
Read More
Brochure
Get an insight on our presence during the upcoming ISPOR Europe conference.
Read More
Article
ABSTRACTBACKGROUND: Recognizing the growing need for robust evidence about treatment effectiveness in real-world populations, the Good Research for Comparative Effectiveness (GRACE) guidelines have been developed for noninterventional studies of comparative effectiveness to determine which studies are sufficiently rigorous to be reliable enough for use in health...
Explore More
White Paper
The growth in Medical Science Liaisons (MSLs) is being driven by the need to communicate increasingly complex scientific information associated with changing biopharma product portfolios and the development of personalized medicines with new modes of action, particularly for oncology and autoimmune disorders. As a key member of the Medical Affairs team – which acts as a...
Explore More